Bone marrow transplantation as a therapy for autosomal dominant osteopetrosis type 2 in mice.

Autor: Alam I; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Gerard-O'Riley RL; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Acton D; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Hardman SL; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Murphy M; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Alvarez MB; Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA., Blosser RJ; Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA., Sinn A; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA., Srour EF; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA., Kacena MA; Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA., Econs MJ; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Jazyk: angličtina
Zdroj: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2022 Sep; Vol. 36 (9), pp. e22471.
DOI: 10.1096/fj.202200678R
Abstrakt: Autosomal dominant osteopetrosis type II (ADO2) is a heritable bone disease of impaired osteoclastic bone resorption caused by missense mutations in the chloride channel 7 (CLCN7) gene. Clinical features of ADO2 include fractures, osteomyelitis of jaw, vision loss, and in severe cases, bone marrow failure. Currently, there is no effective therapy for ADO2, and patients usually receive symptomatic treatments. Theoretically, bone marrow transplantation (BMT), which is commonly used in recessive osteopetrosis, could be used to treat ADO2, although the frequency of complications related to BMT is quite high. We created an ADO2 knock-in (p.G213R mutation) mouse model on the 129 genetic background, and their phenotypes mimic the human disease of ADO2. To test whether BMT could restore osteoclast function and rescue the bone phenotypes in ADO2 mice, we transplanted bone marrow cells from 6-8 weeks old male WT donor mice into recipient female ADO2 mice. Also, to determine whether age at the time of transplant may play a role in transplant success, we performed BMT in young (12-week-old) and old (9-month-old) ADO2 mice. Our data indicate that ADO2 mice transplanted with WT marrow achieved more than 90% engraftment up to 6 months post-transplantation at both young and old ages. The in-vivo DXA data revealed that young ADO2 mice transplanted with WT marrow had significantly lower whole body and spine areal bone mineral density (aBMD) at month 6 post-transplantation compared to the ADO2 control mice. The old ADO2 mice also displayed significantly lower whole body, femur, and spine aBMD at months 4 and 5 post-transplantation compared to the age-matched control mice. The in-vivo micro-CT data showed that ADO2 experimental mice transplanted with WT marrow had significantly lower BV/TV at months 2 and 4 post-transplantation compared to the ADO2 control mice at a young age. In contrast, ADO2 control and experimental mice displayed similar BV/TV values for all post-transplantation time points at old age. In addition, serum CTX was significantly higher at month 2 post-transplantation in both young and old ADO2 experimental mice compared to the ADO2 control mice. Serum P1NP levels in young ADO2 experimental mice were significantly higher at baseline and month 2 post-transplantation compared to the ADO2 control mice. These data suggest that BMT may provide, at least, some beneficial effect at both young and adult ages.
(© 2022 Federation of American Societies for Experimental Biology.)
Databáze: MEDLINE
Externí odkaz: